Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion did not result in significantly greater vision recovery at 30 days than oral aspirin but was associated with serious safety concerns. (Funded by Oslo University Hospital and others; TenCRAOS ClinicalTrials.gov number, NCT04526951; EU Clinical Trials number, 2024-517606-29-00.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Stephen James Ryan
Øystein Kalsnes Jørstad
Mona Skjelland
New England Journal of Medicine
Karolinska Institutet
KU Leuven
University of Copenhagen
Building similarity graph...
Analyzing shared references across papers
Loading...
Ryan et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69a75babc6e9836116a23700 — DOI: https://doi.org/10.1056/nejmoa2508515